Eight of nine experts expressed feeling “extremely confident” about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on ...

Please provide your email address to receive an email when new articles are posted on . Cal/BDP is a combination formula, comprised of calcipotriol and betamethasone dipropionate, that treats ...

The Food and Drug Administration (FDA) announced that it has accepted the supplemental New Drug Application (sNDA) for roflumilast foam 0.3% in adults and adolescents with scalp and body psoriasis ...

Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that the United States Patent Office has granted U.S.

HERSHEY, Pa. -- Every second counts for those with life-threatening injuries, especially when help is far away. A new grant will help Penn State researchers develop an innovative foam that helps seal ...

The US Food and Drug Administration (FDA) has agreed to review a new drug application (NDA) for roflumilast foam 0.3% for treating seborrheic dermatitis in patients ages 9 years and older. If approved ...

Two Virginia Tech researchers have been awarded $1.2 million to develop an electronic molecular toolbox that uses machine learning and analytical techniques to support the development of ...